JP2021534201A5 - - Google Patents
Info
- Publication number
- JP2021534201A5 JP2021534201A5 JP2021509893A JP2021509893A JP2021534201A5 JP 2021534201 A5 JP2021534201 A5 JP 2021534201A5 JP 2021509893 A JP2021509893 A JP 2021509893A JP 2021509893 A JP2021509893 A JP 2021509893A JP 2021534201 A5 JP2021534201 A5 JP 2021534201A5
- Authority
- JP
- Japan
- Prior art keywords
- nucleic acid
- acid sequence
- administered
- approximately
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023205807A JP7690713B2 (ja) | 2018-08-20 | 2023-12-06 | レーベル遺伝性視神経症を治療するための組成物及び方法 |
Applications Claiming Priority (15)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810948193.1 | 2018-08-20 | ||
| CN201810948193.1A CN110846392A (zh) | 2018-08-20 | 2018-08-20 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
| CNPCT/CN2018/103937 | 2018-09-04 | ||
| PCT/CN2018/103937 WO2020000641A1 (zh) | 2018-06-29 | 2018-09-04 | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 |
| CN201811221305.X | 2018-10-19 | ||
| CN201811221305.XA CN111073899B (zh) | 2018-10-19 | 2018-10-19 | 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
| CN201811230856.2A CN111068071A (zh) | 2018-10-22 | 2018-10-22 | 基因治疗Leber遗传学视神经病变 |
| CN201811230856.2 | 2018-10-22 | ||
| PCT/CN2018/113799 WO2020082417A1 (zh) | 2018-10-22 | 2018-11-02 | 基因治疗Leber遗传性视神经病变 |
| CNPCT/CN2018/113799 | 2018-11-02 | ||
| PCT/CN2018/118662 WO2020077756A1 (zh) | 2018-10-19 | 2018-11-30 | Nd4蛋白的编码序列及其应用 |
| CNPCT/CN2018/118662 | 2018-11-30 | ||
| PCT/CN2019/070461 WO2020037938A1 (zh) | 2018-08-20 | 2019-01-04 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
| CNPCT/CN2019/070461 | 2019-01-04 | ||
| PCT/CN2019/101538 WO2020038352A1 (en) | 2018-08-20 | 2019-08-20 | Compositions and methods for treating leber's hereditary optic neuropathy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023205807A Division JP7690713B2 (ja) | 2018-08-20 | 2023-12-06 | レーベル遺伝性視神経症を治療するための組成物及び方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2021534201A JP2021534201A (ja) | 2021-12-09 |
| JP2021534201A5 true JP2021534201A5 (enExample) | 2022-08-29 |
| JP7403852B2 JP7403852B2 (ja) | 2023-12-25 |
Family
ID=74668040
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021509893A Active JP7403852B2 (ja) | 2018-08-20 | 2019-08-20 | レーベル遺伝性視神経症を治療するための組成物及び方法 |
| JP2023205807A Active JP7690713B2 (ja) | 2018-08-20 | 2023-12-06 | レーベル遺伝性視神経症を治療するための組成物及び方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023205807A Active JP7690713B2 (ja) | 2018-08-20 | 2023-12-06 | レーベル遺伝性視神経症を治療するための組成物及び方法 |
Country Status (9)
| Country | Link |
|---|---|
| US (2) | US11352645B2 (enExample) |
| EP (1) | EP3840785A4 (enExample) |
| JP (2) | JP7403852B2 (enExample) |
| KR (1) | KR20210068014A (enExample) |
| CN (1) | CN112584874A (enExample) |
| AU (1) | AU2019323434A1 (enExample) |
| CA (1) | CA3109432A1 (enExample) |
| SG (1) | SG11202101032VA (enExample) |
| WO (1) | WO2020038352A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113528510A (zh) | 2018-06-29 | 2021-10-22 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| US20210100856A1 (en) * | 2019-09-11 | 2021-04-08 | Adverum Biotechnologies, Inc. | Methods of treating ocular neovascular diseases using aav2 variants encoding aflibercept |
| CN113025633B (zh) * | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
| MX2024001597A (es) * | 2021-08-06 | 2024-02-15 | Wuhan Neurophth Biotechnology Ltd Company | Composicion y metodo para el tratamiento de la neuropatia optica hereditaria de leber causada por una mutacion en nd4. |
| CN116789772A (zh) * | 2022-03-18 | 2023-09-22 | 北京安龙生物医药有限公司 | Aav5扩容衣壳突变体及其扩容检测方法 |
| WO2024144330A1 (ko) * | 2022-12-29 | 2024-07-04 | 주식회사 엣진 | 레베르 유전성 시신경병증의 미토콘드리아 염기 변이 교정 시스템 |
| CN118320132A (zh) * | 2024-04-26 | 2024-07-12 | 首都医科大学附属北京友谊医院 | 重组腺相关病毒rAAV2/Rec2作为胰腺靶向性载体的应用 |
Family Cites Families (41)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3625214A (en) | 1970-05-18 | 1971-12-07 | Alza Corp | Drug-delivery device |
| US4906474A (en) | 1983-03-22 | 1990-03-06 | Massachusetts Institute Of Technology | Bioerodible polyanhydrides for controlled drug delivery |
| US4789734A (en) | 1985-08-06 | 1988-12-06 | La Jolla Cancer Research Foundation | Vitronectin specific cell receptor derived from mammalian mesenchymal tissue |
| WO1988001213A1 (en) | 1986-08-18 | 1988-02-25 | Clinical Technologies Associates, Inc. | Delivery systems for pharmacological agents |
| US5811128A (en) | 1986-10-24 | 1998-09-22 | Southern Research Institute | Method for oral or rectal delivery of microencapsulated vaccines and compositions therefor |
| US5075109A (en) | 1986-10-24 | 1991-12-24 | Southern Research Institute | Method of potentiating an immune response |
| US4897268A (en) | 1987-08-03 | 1990-01-30 | Southern Research Institute | Drug delivery system and method of making the same |
| JPH08505625A (ja) | 1993-01-11 | 1996-06-18 | ダナ−ファーバー キャンサー インスティチュート | 細胞毒性ｔリンパ球応答の誘導 |
| AU2668897A (en) | 1996-04-19 | 1997-11-12 | Genetic Therapy, Inc. | Gene therapy involving concurrent and repeated administration of adenoviruses and immunosuppressive agents |
| US6207392B1 (en) | 1997-11-25 | 2001-03-27 | The Regents Of The University Of California | Semiconductor nanocrystal probes for biological applications and process for making and using such probes |
| CA2403804A1 (en) * | 2000-03-21 | 2001-09-27 | Curagen Corporation | Vegf-modulated genes and methods employing them |
| WO2002082904A2 (en) * | 2001-04-13 | 2002-10-24 | The Trustees Of The University Of Pennsylvania | Method of treating or retarding the development of blindness |
| BRPI0511764B8 (pt) | 2004-06-01 | 2021-05-25 | Avigen Inc | método de prevenção de agregação de vírions de vírus adeno-associado recombinante (raav) em uma preparação purificada de virions raav |
| US20130022979A1 (en) * | 2005-04-18 | 2013-01-24 | Genesis Genomics Inc. | 3.4kb MITOCHONDRIAL DNA DELETION FOR USE IN THE DETECTION OF CANCER |
| PT1880008E (pt) * | 2005-05-03 | 2015-08-27 | Inserm Inst Nat De La Santé Et De La Rech Médicale | Expressão de proteína mitocondrial através de uma abordagem alotópica melhorada |
| CA2667705A1 (en) * | 2006-10-23 | 2008-05-29 | University Of Florida Research Foundation, Inc. | Suppression of mitochondrial oxidative stress |
| EP2121914B1 (en) * | 2007-02-16 | 2014-08-20 | John Guy | Mitochondrial nucleic acid delivery systems |
| HRP20140405T1 (hr) * | 2007-06-20 | 2014-06-20 | Galapagos N.V. | Molekularni ciljevi i metode za identificiranje spojeva za lijeäśenje degenerativnih bolesti kostiju i zglobova |
| CN102994500B (zh) * | 2008-10-22 | 2015-04-01 | 夸克制药公司 | 治疗眼部疾病的方法 |
| ES2680915T3 (es) | 2010-01-28 | 2018-09-11 | The Children's Hospital Of Philadelphia | Plataforma de fabricación escalable para la purificación de vectores virales y vectores virales purificados de este modo para su utilización en terapia génica |
| CN102517304B (zh) | 2011-12-16 | 2013-08-28 | 中国农业科学院生物技术研究所 | 重组葡萄糖氧化酶的优化基因及其表达载体和应用 |
| US20160289674A1 (en) * | 2012-04-02 | 2016-10-06 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of membrane proteins |
| CN102634527B (zh) * | 2012-04-11 | 2013-11-06 | 华中科技大学同济医学院附属同济医院 | 重组人nadh脱氢酶亚单位4基因及其表达载体构建方法 |
| TWI690322B (zh) | 2012-10-02 | 2020-04-11 | 法商傳斯堅公司 | 含病毒的調配物及其使用 |
| SG11201702116VA (en) * | 2014-09-17 | 2017-04-27 | Univ Iowa Res Found | Viral rna segments as immunomodulatory agents and vaccine components |
| CN104450747B (zh) * | 2014-09-23 | 2018-02-09 | 武汉纽福斯生物科技有限公司 | 用于治疗Leber遗传性视神经病变的重组腺相关病毒‑NADH脱氢酶亚单位4基因全长以及药剂 |
| CN108024544B (zh) * | 2015-07-13 | 2022-04-29 | 桑格摩生物治疗股份有限公司 | 用于核酸酶介导的基因组工程化的递送方法及组合物 |
| CA2973885A1 (en) * | 2016-07-21 | 2018-01-21 | Stealth Biotherapeutics Corp | Therapeutic compositions including mitochondrial-targeted creatine compounds and uses thereof to treat and prevent mitochondrial diseases and conditions |
| WO2018102672A1 (en) * | 2016-12-04 | 2018-06-07 | Alavi Khorassani Moghadam Marcel Victor | Methods for treating diseases related to mitochondrial stress |
| US20180207293A1 (en) * | 2017-01-25 | 2018-07-26 | 2C Tech Corp. | Nanoparticles for sustained ophthalmic drug delivery and methods of use |
| WO2019033119A1 (en) * | 2017-08-11 | 2019-02-14 | Unity Biotechnology, Inc. | TREATMENT OF OPHTHALMIC CONDITIONS SUCH AS MACULAR DEGENERATION, GLAUCOMA AND DIABETIC RETINOPATHY USING PHARMACEUTICAL AGENTS THAT ELIMINATE SENESCENT CELLS |
| EP3781695A4 (en) * | 2018-04-16 | 2022-01-26 | The Children's Hospital of Philadelphia | IMPORT OF MITOCHONDRIAL RNA FOR TREATMENT OF MITOCHONDRIAL DISEASE |
| JP7470057B2 (ja) * | 2018-06-11 | 2024-04-17 | セルジュ フィトゥシ | 組み換えａａｖベクター及びその使用方法 |
| CN113528510A (zh) * | 2018-06-29 | 2021-10-22 | 武汉纽福斯生物科技有限公司 | 治疗遗传性视神经病变的组合物和方法 |
| WO2020000641A1 (zh) | 2018-06-29 | 2020-01-02 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位蛋白的核酸及其应用 |
| CN111073899B (zh) | 2018-10-19 | 2021-01-01 | 武汉纽福斯生物科技有限公司 | 一种编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
| CN110846392A (zh) | 2018-08-20 | 2020-02-28 | 武汉纽福斯生物科技有限公司 | 一种重组腺相关病毒或含其的试剂盒及其应用 |
| WO2020010491A1 (zh) | 2018-07-09 | 2020-01-16 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位4蛋白的核酸及其应用 |
| CN111068071A (zh) | 2018-10-22 | 2020-04-28 | 武汉纽福斯生物科技有限公司 | 基因治疗Leber遗传学视神经病变 |
| CA3109432A1 (en) | 2018-08-20 | 2020-02-27 | Wuhan Neurophth Biotechnology Limited Company | Compositions and methods for treating leber's hereditary optic neuropathy |
| CN113025633B (zh) | 2019-12-09 | 2024-08-27 | 武汉纽福斯生物科技有限公司 | 编码人nadh脱氢酶亚单位1蛋白的核酸及其应用 |
-
2019
- 2019-08-20 CA CA3109432A patent/CA3109432A1/en active Pending
- 2019-08-20 JP JP2021509893A patent/JP7403852B2/ja active Active
- 2019-08-20 KR KR1020217007727A patent/KR20210068014A/ko not_active Ceased
- 2019-08-20 SG SG11202101032VA patent/SG11202101032VA/en unknown
- 2019-08-20 EP EP19853225.1A patent/EP3840785A4/en not_active Withdrawn
- 2019-08-20 CN CN201980054770.5A patent/CN112584874A/zh active Pending
- 2019-08-20 WO PCT/CN2019/101538 patent/WO2020038352A1/en not_active Ceased
- 2019-08-20 AU AU2019323434A patent/AU2019323434A1/en not_active Abandoned
-
2021
- 2021-02-22 US US17/181,849 patent/US11352645B2/en active Active
-
2022
- 2022-04-22 US US17/726,833 patent/US20220259619A1/en not_active Abandoned
-
2023
- 2023-12-06 JP JP2023205807A patent/JP7690713B2/ja active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lipworth et al. | Effect of ciclesonide and fluticasone on hypothalamicpituitary-adrenal axis function in adults with mild-to-moderate persistent asthma | |
| Knutsson et al. | Effects of intranasal glucocorticoids on endogenous glucocorticoid peripheral and central function | |
| Kelly | Comparison of inhaled corticosteroids | |
| KR20010110803A (ko) | 약제학적 조성물 | |
| JP2024530954A5 (enExample) | ||
| JP2024518735A5 (enExample) | ||
| Mehdipour et al. | Role of corticosteroids in oral lesions | |
| Güven | Different potent glucocorticoids, different routes of exposure but the same result: iatrogenic Cushing’s syndrome and adrenal insufficiency | |
| US20110144072A1 (en) | Antiglucocorticoid Therapy for the Prevention of Neurological Damage in Premature Infants | |
| WO2014105978A1 (en) | Methods of treatment using bevacizumab | |
| Helfer et al. | Corticosteroids and adrenal suppression: characterising and avoiding the problem | |
| JP2024543509A5 (enExample) | ||
| JP2022537555A5 (enExample) | ||
| JP2024519196A5 (enExample) | ||
| JP2022500364A5 (enExample) | ||
| IL312515A (en) | Bispecific cd16a binders | |
| Ververeli et al. | Oral corticosteroid-sparing effects of inhaled corticosteroids in the treatment of persistent and acute asthma | |
| JP2024540304A5 (enExample) | ||
| Vanzieleghem et al. | A comparison of budesonide and beclomethasone dipropionate nasal aerosols in ragweed-induced rhinitis | |
| Myers | Treatment of multiple sclerosis with ACTH and corticosteroids | |
| JP2024516886A5 (enExample) | ||
| JP2024527001A5 (enExample) | ||
| IL312514A (en) | Corticosteroid reduction in treatment with anti-cd38 antibodies | |
| Smith et al. | A controlled trial of beclomethasone dipropionate for asthma | |
| Shapiro | Corticosteroids in the treatment of allergic disease: principles and practice |